Point72 (DIFC)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$18K Sell
400
-13,800
-97% -$644K ﹤0.01% 869
2025
Q2
$657K Sell
14,200
-4,800
-25% -$236K 0.02% 504
2025
Q1
$1.16M Sell
19,000
-262,000
-93% -$15.3M 0.05% 437
2024
Q4
$15.9M Sell
281,000
-33,500
-11% -$1.87M 0.58% 27
2024
Q3
$16.3M Buy
314,500
+250,600
+392% +$11.8M 0.55% 37
2024
Q2
$2.65M Buy
63,900
+30,600
+92% +$1.37M 0.09% 269
2024
Q1
$1.81M Buy
+33,300
New +$1.7M 0.06% 420

Other funds holding BMY

Point72 (DIFC)'s BMY Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Bristol-Myers Squibb (BMY) in Q3 2025: 107,251 shares worth $4.84M. The stake represents 0.32% of the portfolio and ranks #80 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in BMY as recently as Q4 2024.

Point72 (DIFC) first reported a position in BMY in Q2 2024 and has held it in 3 quarters since. The position peaked at $26.6M in Q2 2024. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

  • Point72 (DIFC) held 107,251 shares of Bristol-Myers Squibb worth $4.84M as of Q3 2025.
  • Bristol-Myers Squibb was a new Point72 (DIFC) position in Q3 2025.
  • Bristol-Myers Squibb made up 0.32% of Point72 (DIFC)'s portfolio in Q3 2025, its #80 holding.
  • Point72 (DIFC) first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s Bristol-Myers Squibb position peaked at $26.6M in Q2 2024.
  • 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.